key: cord-0866881-y77a1lem
authors: Can, Alp; Coskun, Hakan
title: The rationale of using mesenchymal stem cells in patients with COVID‐19‐related acute respiratory distress syndrome: What to expect
date: 2020-07-21
journal: Stem Cells Transl Med
DOI: 10.1002/sctm.20-0164
sha: e7ef823faa03a5ff51c9e2de3458b6da1bb0429a
doc_id: 866881
cord_uid: y77a1lem

The severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2)‐caused coronavirus disease 2019 (COVID‐19) pandemic has become a global health crisis with an extremely rapid progress resulting in thousands of patients requiring intensive care unit (ICU) treatment who may develop acute respiratory distress syndrome (ARDS). So far, no specific antiviral therapeutic agent has been demonstrated to be effective for COVID‐19; therefore, the clinical management is largely supportive and depends on the patients' immune response leading to a cytokine storm followed by lung edema, dysfunction of air exchange, and ARDS, which could lead to multiorgan failure and death. Given that human mesenchymal stem cells (MSCs) from various tissue sources have revealed successful clinical outcomes in many immunocompromised disorders by inhibiting the overactivation of the immune system and promoting endogenous repair by improving the microenvironment, there is a growing demand for MSC infusions in patients with COVID‐19‐related ARDS in the ICU. In this review, we have documented the rationale and possible outcomes of compassionate use of MSCs, particularly in patients with SARS‐CoV‐2 infections, toward proving or disproving the efficacy of this approach in the near future. Many centers have registered and approved, and some already started, single‐case or phase I/II trials primarily aiming to rescue their critical patients when no other therapeutic approach responds. On the other hand, it is also very important to mention that there is a good deal of concern about clinics offering unproven stem cell treatments for COVID‐19. The reviewers and oversight bodies will be looking for a balanced but critical appraisal of current trials.

The coronavirus disease 2019 pandemic, caused by a novel beta coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), possessing a single-strand, positivesense RNA genome (26-32 kilobases in length), 1 is the definition of the greatest health challenge of our times. Since its emergence in Guangdong, Southern China, late last year, the virus has spread to 213 countries in every continent except Antarctica as of late June 2020. 2, 3 Cases are still rising, especially in Russia, Brazil, the United States, and the United Kingdom, even though a declining trend was noted in deaths in recent weeks. Countries are struggling with slowing down the spread of the virus by testing and treating patients, quarantining infected citizens, limiting or banning leisure travel, prohibiting large social gatherings, and closing schools. As of June 23, 2020, more than 9.2 million cases have been reported worldwide with around 475 000 deaths. 3 The case fatality rate (CFR) varies from 2.3% to 14.8% depending on the demographics of the nation or region, age, severity of the disease, and comorbidities. Overall, the CFR was reported to be around 11% worldwide among COVID-19-positive cases, and the ratio of serious or critical cases is around 2%. Older adults between the ages of 70 and 80 years have a CFR of 8.0%, and those aged more than 80 years have a CFR of 14.8%. 4 The CFR was reported to 49.0% among critical cases and was significantly high among those with preexisting comorbid conditions-10.5% for cardiovascular disease, 7.3% for diabetes, 6.3% for chronic respiratory disease, 6.0% for hypertension, and 5.6% for cancer. 4 In contrast, more than 50% of children (younger than 18 years) experienced mild symptoms or were asymptomatic, with fewer than 6% of children developing severe symptoms. 5 COVID-19 has an incubation period of 2 to 14 days; the mean incubation period is 5.2 days. 6, 7 Although around 30% of infected people are asymptomatic, the onset of illness is characterized by a series of clinical symptoms from mild to severe, including fever (98% of patients), cough, shortness of breath and/or chest pain (76%), and myalgia or fatigue (44%). 8 Less common symptoms are sputum production, sore throat, loss of taste and smell, headache, hemoptysis, and diarrhea. Therefore, disease stage is classified according to the patient's clinical symptoms and laboratory findings as (a) mild type: mild clinical symptoms without pneumonia; (b) common type: fever, respiratory tract and other symptoms with pneumonia; (c) severe type: respiratory distress (respiratory rate is higher than 30 times per minute; in resting state, oxygen saturation is lower than 93%; partial pressure of oxygen [PaO 2 ] to fraction of inspired oxygen [FiO 2 ] ratio lower than 300 mmHg); (d) critical type: respiratory failure requiring mechanical ventilation, shock, and other organ failure requiring intensive care unit (ICU) monitoring and treatment. 9 In addition, patients with acute cardiac injury present with tachycardia or bradycardia. Critically ill individuals may also have acidosis and increased lactate. 6 No specific antiviral therapeutic agents or vaccines for have been proven to be effective so far. Several therapies, such as ribavirin, remdesivir, favipiravir, and oseltamivir, are under investigation, 4,10 but the antiviral efficacy of these drugs is not yet known. The supportive approach includes corticosteroids, antibiotics, anticoagulants, and oxygen therapy. Recently, convalescent plasma therapy for COVID-19 has been under consideration to prove its safety and efficacy. Promising results (32 participants) and 48 ongoing trials were accumulated in a Cochrane analysis. 11 As defined below, cytokine storm (high serum levels of GSCF, 

The diagnosis of COVID-19 is performed by the detection of the virus in respiratory secretions (throat, nasopharynx, sputum, and endotracheal aspirates and bronchoalveolar lavage) by sensitive antigen tests such as polymerase chain reaction assay, even though the testing efficiency is around 60% to 70% in sputum and nasal swab samples. 12 Besides common radiographic tests such as x-ray and computed tomography (CT) imaging, more sophisticated serologic and genomic tests are also available including the full genome analysis by

Although mesenchymal stem/stromal cell (MSC) administration is an unproven stem cell therapy approach for COVID-19 patients, there is a growing demand for new therapies among patients and healthcare workers. Due to preclinical findings and few current clinical data set, MSCs possess remarkable immunomodulatory features, and thus have the potential in recovering the pulmonary microenvironment, intercept pulmonary fibrosis, and cure lung dysfunction in COVID-19 pneumonia and respiratory distress syndrome.

However, it is also noteworthy to point out that there is a good deal of concern about clinics offering unproven stem cell treatments for COVID-19, and reviewers will be looking for a balanced but critical appraisal of current trials.

next-generation sequencing. 13 As summarized in Table 1 , blood test findings include normal/low leukocyte counts with high C-reactive protein (CRP). There may be lymphopenia; fewer than 1000 lymphocytes has been associated with severe disease. The platelet count is usually normal or slightly low. The CRP and erythrocyte sedimentation rate are generally elevated; however, procalcitonin levels are usually normal. A high procalcitonin level may imply a bacterial coinfection.

The aspartate transaminase (AST) and alanine transaminase (ALT), prothrombin time, creatinine, D-dimer, creatinine phosphokinase, and lactate dehydrogenase may be elevated, and high levels are associated with severe disease. 14,15 CT chest scans are usually abnormal even in those with no symptoms or mild disease. However, starting from the common cases, CT imaging shows infiltrates, ground-glass opacities, and subsegmental consolidation. It may also have abnormal results in asymptomatic patients or patients with no clinical evidence of lower respiratory tract involvement. In fact, abnormal CT scans have been used to diagnose COVID-19 in suspected virus-negative cases; many of these patients become positive on repeat testing. 16 According to the laboratory tests published so far, in a subset of patients with COVID-19, clinical progress is associated with an activation of an inflammatory cascade, called "cytokine storm syndrome," which is mainly due to activated T-helper 1 (Th1) and T-helper 17 (Th17) cell responses. 17, 18 It is a diverse set of conditions unified by a clinical phenotype of systemic inflammation, multiorgan failure, and hyperferritinemia 19 and is associated with a wide variety of virus infections, such as severe acute respiratory coronaviruses (including SARS-CoV-2), influenza virus, and dengue virus, and noninfectious diseases. 20 Some patients with COVID-19 progress to this hyperinflammatory condition, often with pulmonary involvement resembling the secondary hemophagocytic syndrome, which is commonly triggered by viral infections. 21 This systemic hyperinflammation results in inflammatory lymphocytic and monocytic infiltration of the lung and heart, causing ARDS and cardiac failure. Huang et al 8 noted that patients with COVID-19 both in the ICU and not requiring the ICU demonstrated higher cytokine profiles compared with healthy adults, characterized by increased IL-1β, IL-2, IL-7, IL-8, IL-9, IL-10, IL-17, granulocyte-colony stimulating factor (GCSF), IP-10, MCP-1, MIP-1α, TNF-α, and some growth factors such as platelet-derived growth factor and vascular endothelial growth factor (VEGF) 8 (Table 1) .

Huang et al further reported that plasma concentrations of IL-2, IL-7, IL-10, GCSF, IP-10, MCP-1, MIP-1α, and TNF-α were higher in patients in the ICU than in patients not in the ICU. On the other hand, plasma levels of IL-5, IL-12p70, IL-15, eotaxin, and RANTES were found to be comparable between healthy adults and infected patients.

Predictors of mortality in a recent retrospective study of 150 confirmed COVID-19 cases in Wuhan, China, included elevated IL-6. 22 Taken together, cytokine profiles of patients seem to lead to mortality that is directly related to virus-driven hyperinflammation. 23 As demonstrated in patients with severe acute respiratory syndrome (SARS) more than 15 years ago, elevated levels of T-helper cell-originated proinflammatory cytokines, that is, interferon (IFN)-γ, IL-1B, IL-6, IL-12, IP-10, neutrophil-originated chemokine IL-8, and MCP-1, were associated with pulmonary inflammation and extensive lung damage. 24 Besides the cytokine storm, COVID-19-related clinical manifestations reflect that patients develop lymphocytic endotheliitis as evidenced by the impairment of many organs, including kidney, heart, small intestine, and lungs. 26 Therefore, COVID-19 pathogenesis in the endothelial cells causes a vascular disease state during which 89% of T A B L E 1 The immunological, serological, and histopathological profile of patients with COVID-19

Serum/blood tests Lung histopathology IFN-γ ", IL-1β ", IP-10 ", MCP-1 ", GCSF ", IL-2 ", IL-6 ", IL-7 ", IL-8 ", IL-9 ", IL-10 ", IL-17 ", MIP-1α ", MCP-1 ", IP-10 ", TNF-α "

AST ", ALT ", LDH ", CPK ", creatinine ", CRP ", ESR ", γ-GT ", α-HBDH ", D-dimer ", total bilirubin ", ferritin ", prothrombin time ", cardiac troponin ", procalcitonin ", albumin #, hemoglobin #, eosinophils #, basophils #, neutrophils ", monocytes #, CD14 + CD16 + monocytes ", lymphocytes # Atypical enlarged pneumocytes and/or desquamation of pneumocytes Hyaline membrane formation Cellular or proteinaceous exudates Alveolar hemorrhage Fibrinoid necrosis of small vessels Multinucleated syncytial cells Interstitial accumulation of mononuclear cells (monocytes and T cells) Endothelial dysfunction associated with apoptosis

Note: The degree of elevation (") or decline (#) and histopathological changes vary by the severity of patient's clinical status from mild to severe cases of acute respiratory distress syndrome. Abbreviations: α-HBDH, α-hydroxybutyrate dehydrogenase; γ-GT, gamma-glutamyl transpeptidase; ALT, alanine transaminase; AST, aspartate transaminase; CPK, creatine phosphokinase; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; GCSF, granulocyte-colony stimulating factor; IFN-γ, interferon gamma; IL, interleukin; IP-10, IFN-γ inducible protein 10 (also known as CXC-chemokine ligand 10); MCP-1, monocyte chemoattractant protein 1 (also known as CC-chemokine ligand 2); LDH, lactic acid dehydrogenase; MIP-1α, macrophage inflammatory protein 1α (also known as CC-chemokine ligand 3); TNF-α, tumor necrosis factor-α.

hospitalized patients showed subsegmental vascular enlargement on their initial CT scans. 27 Studies have also reported evidence of a COVID-19-associated coagulopathy. It has been shown that 90% of patients with pneumonia had increased coagulation activity, marked by elevated D-dimer, a fibrin degradation thromboembolic marker 28 predicting a poor prognosis in COVID-19.

ARDS, by definition, is a clinical state characterized by an acute presentation of severe and refractory hypoxemia, decreased airway compliance, microscopic evidence of diffuse alveolar damage, and bilateral pulmonary infiltrates excluding cardiac-related edema. 29 Respiratory failure from ARDS has been reported as the leading cause of mortality in COVID-19 cases. 22 Around 10% to 20% of patients with severe COVID-19 may develop shortness of breath, frequently in the second

week of the disease, which might be accompanied by or progress to hypoxemia. 8 The mean period from onset of symptoms to dyspnea was reported as 5 days, hospitalization 7 days, and the onset of ARDS 8 to 9 days. 14 Respiratory damage will inevitably progress into ARDS, defined as PaO 2 /FiO 2 lower than 300 mmHg, during days 8 to 14 of the illness, as well as resulting in noncardiogenic pulmonary edema and mechanical ventilation. 8, 30 ARDS constitutes an acute hypoxemic respiratory failure that originates mainly from an increase in lung endothelial and epithelial permeability, which result in outflow of fluid into alveoli, leading to noncardiogenic pulmonary edema and decreased arterial oxygenation.

Damage to the lung parenchyma results from multiple mechanisms, including direct injury by the inflaming agent (eg, bacteria and their products, viral invasion, and acid injury after aspiration), by harm in resulting from hyperactivation of the immune system, and by mechanical stretch-induced damage caused by mechanical ventilation. 31 The pathologic features of ARDS in alveoli and their microenvironment in COVID-19 greatly resemble those seen in SARS and MERS infections, 32, 33 including uni/bilateral diffuse alveolar parenchyma damage with cellular fibromyxoid exudates, desquamation of pneumocytes, and hyaline membrane formation 34 (Table 1) 

MSCs can be isolated from various tissue sources. The selection of the source is based on their logistical, practical, and in vitro characteristics. Currently, the main sources of MSCs are bone marrow, umbilical cord stroma, adipose tissue, and dental pulp.

Bone marrow mesenchymal stem cells (BM-MSCs) are multipotent cells that are able to differentiate into mesodermal lineage. 46 They are isolated from bone marrow aspirates and subsequently expand in vitro. They have been shown to express a variety of cell surface markers, including CD44, CD73, CD105, and CD146, but they lack hemopoietic markers CD11b, CD14, CD34, and CD45. 47 

Human umbilical cord stroma, which is known as Wharton's jelly, is a rich source of primitive mesenchymal stromal cells (UC-MSCs or WJ-MSCs). UC-MSCs are multipotent cells that can be differentiated into mesodermal as well as to neuronal lineages. 49 

Several studies revealed that adipose tissues contain MSCs, termed adipose tissue-derived stem cells (ADSCs). They are preferentially located in the stromal vascular fraction of isolated adipose explants. In conditional cultures, ADSCs exhibit a multipotent differentiation capacity into cell types originated from three germ layers. 59 ADSCs express CD44, CD73, CD90, and CD105 and are negative for CD31 and CD45. 60 ADSCs can induce proliferation of IL-10-producing regulatory B cells that regulate the immune system by anti-inflammatory potential. 61 Therefore, ADSCs can be used in the treatment of diverse immune-related disorders, including graft-vs-host disease. 62 As the isolation of autologous ADSCs is relatively simple and less invasive compared with BM-MSCs, they have been the first choice in many trials. However, ADSCs still exhibited only moderate benefits in clinical trials.

Dental pulp MSCs (DP-MSCs), primarily isolated from the dental pulp, 63 can also be isolated from deciduous teeth, apical papilla, periodontal ligament, dental follicles, and gingiva. 64 They have the capacity to differentiate into mesodermal lineage under certain conditions in vitro. 36 However, DP-MSCs also express stemness-related markers similar to embryonic stem cells, such as Oct-3/4, Nanog, and Sox-2. 65 Like MSCs from other tissues, DP-MSCs also have a strong immunomodulatory ability with a higher suppression rate of T-lymphocyte growth capacities. 66 Moreover, DP-MSCs can suppress lymphocyte proliferation and increase the number of regulatory T cells and IL-10 while decreasing IL-4 and IFN-γ levels. 67 Therefore, dental pulp is considered a novel MSC source to use for the treatment of autoimmune and inflammatory diseases. and tissue inhibitor of matrix metalloproteinases (TIMPs) TIMP1 and TIMP3 decreased after MSC treatment of pressure overload hypertrophy. 74 Moreover, administration of MSCs prevented irradiationinduced lung fibrosis by reducing production of inflammatory cytokines, proliferation of fibroblasts, and accumulation of collagen. 75 They also limit the fibrotic response by reducing myofibroblast differentiation from epithelial cells and fibroblasts. 76 Thus, MSCs are considered as critical elements in ECM remodeling after tissue damage; therefore, they represent a therapeutic tool in recovering normal tissue functions in fibrosis.

Recent studies suggest that the signals responsible for the therapeutic effects of MSCs are at least partially linked to the production of EVs.

Simply, EVs are small, round packages Type-I alveolar cell of secretory products enclosed by a phospholipid bilayer membrane, which carry several bioactive components. 77 Although confusion on the nomenclature of EVs exists in the literature, EVs are currently classified into exosomes, microvesicles, and apoptotic bodies according to their cellular origin. 78 EVs encapsulate cargo molecules, including proteins, microRNA, and mRNAs, from their cell of origin. 79 when it is added to cells in which p38 kinase has been activated. 101 However, the augmentation effect of PGE 2 on IL-6 levels is independent of p38 kinase activity, and p38 kinase inhibitors are able to inhibit IL-6 production in activated macrophages by inhibiting PGE 2 synthesis. Collectively, MSC-derived PGE 2 has a central role in controlling the COVID-19-induced IL-6-and IL-10-mediated cytokine storm.

MSCs also have the potential of releasing antibacterial factors and therefore stimulating monocyte/macrophage phagocytosis. 96 The this study were the small sample size and short-term follow-up as well as the lack of statistical power and randomization. 117 However, this mini trial also showed that infused MSCs remained negative for angiotensin-converting enzyme 2, a cell surface receptor that is required for SARS-CoV-2 virus to attach to the alveolar epithelial cells, 118 meaning that transplanted MSCs did not differentiate and remained free of virus. 119 In an extremely short time interval, as of June 5, 2020, 36 MSC trials for COVID-19 were registered to ClinicalTrials.gov, primarily aiming to rescue patients with severe or critical COVID-19 (Table 2) .

Apparently, the number of trials will rise, because we are aware that in the corresponding author's country of residence, two phase II/III tri- 

Epidemiology, genetic recombination, and pathogenesis of coronaviruses

COVID-19) Dashboard. World Health Organization Web site

COVID-19 Coronavirus Pandemic. Worldometer.info Web site

Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention

Epidemiology of COVID-19 among children in China

Coronavirus disease 2019 (COVID-19): a clinical update

Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

CT image visual quantitative evaluation and clinical classification of coronavirus disease (COVID-19)

Drug treatment options for the 2019-new coronavirus (2019-nCoV)

Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review

Detection of SARS-CoV-2 in different types of clinical specimens

An update on SARS-CoV-2/COVID-19 with particular reference to its clinical pathology, pathogenesis, immunopathology and mitigation strategies

A review of coronavirus disease-2019 (COVID-19)

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Use of chest CT in combination with negative RT-PCR assay for the 2019 novel coronavirus but high clinical suspicion

TH17 responses in cytokine storm of COVID-19: an emerging target of JAK2 inhibitor fedratinib

An interferon-gamma-related cytokine storm in SARS patients

Review: cytokine storm syndrome: looking toward the precision medicine era

Into the eye of the cytokine storm

Adult haemophagocytic syndrome

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China

COVID-19: consider cytokine storm syndromes and immunosuppression

Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome

MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile

Endothelial cell infection and endotheliitis in COVID-19

Facing COVID-19 in the ICU: vascular dysfunction, thrombosis, and dysregulated inflammation

D-dimer as marker for microcirculatory failure: correlation with LOD and APACHE II scores

The definition of ARDS revisited: 20 years later

Clinical characteristics of coronavirus disease 2019 in China

The acute respiratory distress syndrome

The clinical pathology of severe acute respiratory syndrome (SARS): a report from

A clinicopathological study of three cases of severe acute respiratory syndrome (SARS)

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

Multilineage potential of adult human mesenchymal stem cells

Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement

The meaning, the sense and the significance: translating the science of mesenchymal stem cells into medicine

Mesenchymal stromal cells and the innate immune response

Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications

Cytokine expression by human marrow-derived mesenchymal progenitor cells in vitro: effects of dexamethasone and IL-1 alpha

Ex vivo expansion and subsequent infusion of human bone marrowderived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use

Mesenchymal stromal cells anno 2019: dawn of the therapeutic era? Concise review

First decade of clinical trials and published studies with mesenchymal stromal cells from umbilical cord tissue

Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19

SARS-CoV pathogenesis is regulated by a STAT1 dependent but a type I, II and III interferon receptor independent mechanism

Non-hematopoietic bone marrow stem cells: molecular control of expansion and differentiation

Bone marrow mesenchymal stem cells: biological properties and their role in hematopoiesis and hematopoietic stem cell transplantation

Human mesenchymal stem cells modulate allogeneic immune cell responses

Biology of stem cells in human umbilical cord stroma: in situ and in vitro surveys

Isolation, culture, and characterization of human umbilical cord stroma-derived mesenchymal stem cells

The assessment of the in vivo to in vitro cellular transition of human umbilical cord multipotent stromal cells

Clarification of the nomenclature for MSC: the International Society for Cellular Therapy position statement

Immunosuppressive properties of Wharton's jelly-derived mesenchymal stromal cells in vitro

Human umbilical cord mesenchymal stem cells inhibit the function of allogeneic activated Vγ9Vδ2 T lymphocytes in vitro

Immune properties of human umbilical cord Wharton's jelly-derived cells

Mesenchymal stem/stromal cells from neonatal tissues

Umbilical cord mesenchymal stromal cell transplantations: a systemic analysis of clinical trials

Expanded umbilical cord mesenchymal stem cells (UC-MSCs) as a therapeutic strategy in managing critically ill COVID-19 patients: the case for compassionate use

Adipose tissue stem cells for therapy: an update on the progress of isolation, culture, storage, and clinical application

Stromal cells from the adipose tissue-derived stromal vascular fraction and culture expanded adipose tissue-derived stromal/stem cells: a joint statement of the International Federation for Adipose Therapeutics and Science (IFATS) and the International Society for Cellular Therapy (ISCT)

Adipose tissue-derived mesenchymal stem cells induce expansion of interleukin-10-producing regulatory B cells and ameliorate autoimmunity in a murine model of systemic lupus erythematosus

Adipose tissue-derived mesenchymal stem cells have in vivo immunosuppressive properties applicable for the control of the graft-versus-host disease

Postnatal human dental pulp stem cells (DPSCs) in vitro and in vivo

Immunomodulatory properties of dental tissue-derived mesenchymal stem cells: implication in disease and tissue regeneration

Expression pattern of Oct-4, Sox2, and c-Myc in the primary culture of human dental pulp derived cells

Multipotent mesenchymal stem cells with immunosuppressive activity can be easily isolated from dental pulp

The comparison of the immunologic properties of stem cells isolated from human exfoliated deciduous teeth, dental pulp, and dental follicles

Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases

C3a and C5a are chemotactic factors for human mesenchymal stem cells, which cause prolonged ERK1/2 phosphorylation

Human mesenchymal stem cells program macrophage plasticity by altering their metabolic status via a PGE(2)-dependent mechanism

TNFα-stimulated gene-6 (TSG6) activates macrophage phenotype transition to prevent inflammatory lung injury

Kynurenic acid, an IDO metabolite, controls TSG-6-mediated immunosuppression of human mesenchymal stem cells

Leptin-receptor-expressing mesenchymal stromal cells represent the main source of bone formed by adult bone marrow

Reverse remodeling is associated with changes in extracellular matrix proteases and tissue inhibitors after mesenchymal stem cell (MSC) treatment of pressure overload hypertrophy

Injured microenvironment directly guides the differentiation of engrafted Flk-1(+) mesenchymal stem cell in lung

Therapeutic potential of umbilical cord mesenchymal stem cells for inhibiting myofibroblastic differentiation of irradiated human lung fibroblasts

Mesenchymal stem cells secrete immunologically active exosomes

Extracellular vesicles: exosomes, microvesicles, and friends

Mesenchymal stromal cell-derived extracellular vesicles for regenerative therapy and immune modulation: progress and challenges toward clinical application

Introduction to extracellular vesicles: biogenesis, RNA cargo selection, content, release, and uptake

Extracellular vesicles: potential roles in regenerative medicine

The secretome of mesenchymal stromal cells: role of extracellular vesicles in immunomodulation

Mesenchymal stromal cells and immunomodulation: a gathering of regulatory immune cells

Efficient scalable production of therapeutic microvesicles derived from human mesenchymal stem cells

Perspectives for future use of extracellular vesicles from umbilical cord-and adipose tissue-derived mesenchymal stem/stromal cells in regenerative therapies-synthetic review

Mesenchymal stem cells enhance recovery and repair following ventilator-induced lung injury in the rat

Therapeutic effects of human mesenchymal stem cell microvesicles in an ex vivo perfused human lung injured with severe E. coli pneumonia

Clinical grade allogeneic human mesenchymal stem cells restore alveolar fluid clearance in human lungs rejected for transplantation

Mitochondrial transfer from bone-marrow-derived stromal cells to pulmonary alveoli protects against acute lung injury

Mesenchymal stem cells use extracellular vesicles to outsource mitophagy and shuttle micro-RNAs

Mitochondrial transfer via tunneling nanotubes is an important mechanism by which mesenchymal stem cells enhance macrophage phagocytosis in the in vitro and in vivo models of ARDS

Fifty years of research in ARDS. Cell-based therapy for acute respiratory distress syndrome. Biology and potential therapeutic value

Therapeutic efficacy of human mesenchymal stromal cells in the repair of established ventilator-induced lung injury in the rat

Conditioned media from mesenchymal stromal cells restore sodium transport and preserve epithelial permeability in an in vitro model of acute alveolar injury

Allogeneic human mesenchymal stem cells restore epithelial protein permeability in cultured human alveolar type II cells by secretion of angiopoietin-1

Therapeutic effects of human mesenchymal stem cells in ex vivo human lungs injured with live bacteria

Paracrine factors from mesenchymal stem cells attenuate epithelial injury and lung fibrosis

Human mesenchymal stem (stromal) cells promote the resolution of acute lung injury in part through lipoxin A4

Therapeutic effects of human mesenchymal stem cell-derived microvesicles in severe pneumonia in mice

Microvesicles derived from human mesenchymal stem cells restore alveolar fluid clearance in human lungs rejected for transplantation

Regulation of macrophage interleukin-6 (IL-6) and IL-10 expression by prostaglandin E2: the role of p38 mitogen-activated protein kinase

Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37

A new mesenchymal stem cell (MSC) paradigm: polarization into a proinflammatory MSC1 or an immunosuppressive MSC2 phenotype

Cell-based therapy to reduce mortality from COVID-19: systematic review and meta-analysis of human studies on acute respiratory distress syndrome

Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study

Intratracheal administration of umbilical cord blood-derived mesenchymal stem cells in a patient with acute respiratory distress syndrome

Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial

In vivo effects of mesenchymal stromal cells in two patients with severe acute respiratory distress syndrome

Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial

Human umbilical cord-derived mesenchymal stem cells for acute respiratory distress syndrome

Strategies to enhance mesenchymal stem cell-based therapies for acute respiratory distress syndrome

Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury

Chinese Clinical Trial Registry. A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19)

Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells

Transplantation of ACE2− mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia

Stem cell-based therapy for coronavirus disease 2019

Mesenchymal stem cells for coronavirus (COVID-19)-induced pneumonia: revisiting the paracrine hypothesis with new hopes?

The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak

Mesenchymal stem cells and management of COVID-19 pneumonia

American Academy of Stem Cell Physicians. The American Academy of Stem Cell Physicians Recommends A Treatment Protocol for COVID-19 to the WHO. News release

Preying on public fears and anxieties in a pandemic: businesses selling unproven and unlicensed "stem cell treatments" for COVID-19

How to cite this article: Can A, Coskun H. The rationale of using mesenchymal stem cells in patients with COVID-19-related acute respiratory distress syndrome: What to expect

The authors declared no potential conflicts of interest.

A.C.: conception and design, manuscript writing; H.C.: manuscript writing.

Data sharing is not applicable to this article as no new data were created or analyzed in this study.

https://orcid.org/0000-0002-5393-6115Hakan Coskun https://orcid.org/0000-0002-7581-3060